GoAI
Get started
Nanobiotix S.A. logo

Nanobiotix S.A.

NBTX

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$43.55

−$0.13 · -0.30%

Aug 21, 4:00 PM ET

Pre-market

$41.65

−$1.90 · -4.36%

Aug 24, 7:00 AM ET

NBTX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

45

Fair Value

Momentum

70

Gaining

Sentiment

49

Mixed

Risk resilience

46

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Industry
Biotechnology
Sector
Healthcare
Headquarters
FR

Market position

Day range

Current $43.55

52-week range

Current $43.55

Open
$43.47
Previous close
$43.68
Volume
74.31K
Market cap
2.2B USD
50-day average
$38.5616
+12.94% above average
200-day average
$31.1754
+39.69% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
983.54M EUR
P/E (TTM)
-69.88×
P/B (TTM)
-20×
P/S (TTM)
61.08×
EV / EBITDA
-81.5×
Earnings yield
-2.55%
Free cash flow yield
-3.61%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
100.00%
Operating margin
-36.49%
Net margin
-80.83%
Return on equity
28.36%
Return on assets
-35.36%
Return on invested capital
-74.29%

Financial health

Debt / equity
-1.13×
Current ratio
1.09×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends1245%70%-1105%-2280%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Gross margin, FY2025: 100.00%Operating margin, FY2021: -1986.36%Operating margin, FY2022: -977.85%Operating margin, FY2023: -73.96%Operating margin, FY2024: 951.21%Operating margin, FY2025: -36.49%Net margin, FY2021: -1775.71%Net margin, FY2022: -1194.33%Net margin, FY2023: -109.64%Net margin, FY2024: 947.59%Net margin, FY2025: -80.83%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Gross margin FY2025 100.00%. Operating margin FY2021 -1986.36%. Operating margin FY2022 -977.85%. Operating margin FY2023 -73.96%. Operating margin FY2024 951.21%. Operating margin FY2025 -36.49%. Net margin FY2021 -1775.71%. Net margin FY2022 -1194.33%. Net margin FY2023 -109.64%. Net margin FY2024 947.59%. Net margin FY2025 -80.83%.

Income trends

Revenue

29.64M EUR+36.83M EUR

Operating income

−10.82M EUR+84.18%

Net income

−23.96M EUR+64.83%
Income trends across reported periods46.67M EUR4.83M EUR−37.01M EUR−78.85M EURRevenue, FY2021: 2.65M EURRevenue, FY2022: 4.78M EURRevenue, FY2023: 36.21M EURRevenue, FY2024: −7.19M EURRevenue, FY2025: 29.64M EUROperating income, FY2021: −52.58M EUROperating income, FY2022: −46.7M EUROperating income, FY2023: −26.78M EUROperating income, FY2024: −68.39M EUROperating income, FY2025: −10.82M EURNet income, FY2021: −47M EURNet income, FY2022: −57.04M EURNet income, FY2023: −39.7M EURNet income, FY2024: −68.13M EURNet income, FY2025: −23.96M EURFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 2.65M EUR. Revenue FY2022 4.78M EUR. Revenue FY2023 36.21M EUR. Revenue FY2024 −7.19M EUR. Revenue FY2025 29.64M EUR. Operating income FY2021 −52.58M EUR. Operating income FY2022 −46.7M EUR. Operating income FY2023 −26.78M EUR. Operating income FY2024 −68.39M EUR. Operating income FY2025 −10.82M EUR. Net income FY2021 −47M EUR. Net income FY2022 −57.04M EUR. Net income FY2023 −39.7M EUR. Net income FY2024 −68.13M EUR. Net income FY2025 −23.96M EUR.
Metric (EUR)FY2025FY2024FY2023FY2022FY2021
Revenue29.64M EUR−7.19M EUR36.21M EUR4.78M EUR2.65M EUR
Gross profit29.64M EUR−7.19M EUR36.21M EUR4.78M EUR2.65M EUR
Research and development23.12M EUR40.54M EUR38.4M EUR32.64M EUR30.38M EUR
Selling, general, and administrative20.22M EUR20.53M EUR22.05M EUR17.86M EUR19.43M EUR
Operating expenses40.46M EUR61.2M EUR62.99M EUR51.48M EUR55.23M EUR
Interest income985K EUR2.63M EUR1.22M EUR256K EUR—
Interest expense10.4M EUR8.09M EUR7.98M EUR5.84M EUR699.49K EUR
Depreciation and amortization1.5M EUR592K EUR551K EUR1.5M EUR1.56M EUR
Operating income−10.82M EUR−68.39M EUR−26.78M EUR−46.7M EUR−52.58M EUR
Net income−23.96M EUR−68.13M EUR−39.7M EUR−57.04M EUR−47M EUR

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
50%
5 beats, 5 misses, 0 met estimates
Average EPS surprise
-28.03%
10 comparable reports
Latest EPS result
-0.46
Estimate 0.3 · Miss by 250.74%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.41-0.1-0.61-1.12Q1 '23No estimateQ4 '23MissQ2 '24BeatQ4 '24BeatQ2 '25MissQ3 '25BeatQ1 '26MissQ3 '26Estimate
Q1 2023, reported Mar 28, 2023: actual -0.948, estimate —, surprise —, Comparison unavailable. Q4 2023, reported Nov 13, 2023: actual -0.875, estimate -0.593, surprise -47.60%, Miss. Q2 2024, reported Apr 24, 2024: actual -0.329, estimate -0.83, surprise +60.40%, Beat. Q4 2024, reported Nov 12, 2024: actual -0.499, estimate -0.512, surprise +2.47%, Beat. Q2 2025, reported Apr 2, 2025: actual -1.01, estimate -0.62, surprise -63.46%, Miss. Q3 2025, reported Sep 30, 2025: actual -0.134, estimate -0.247, surprise +45.89%, Beat. Q1 2026, reported Mar 31, 2026: actual -0.458, estimate 0.304, surprise -250.74%, Miss. Q3 2026, reported Sep 29, 2026: actual —, estimate -0.132, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates57.4M29.1M804.89K-27.49MQ1 '23No estimateQ4 '23MissQ2 '24No estimateQ4 '24MissQ2 '25MissQ3 '25BeatQ1 '26MissQ3 '26Estimate
Q1 2023, reported Mar 28, 2023: actual 1.86M USD, estimate —, surprise —, Comparison unavailable. Q4 2023, reported Nov 13, 2023: actual 3.59M USD, estimate 3.95M USD, surprise -9.09%, Miss. Q2 2024, reported Apr 24, 2024: actual 36.2M USD, estimate —, surprise —, Comparison unavailable. Q4 2024, reported Nov 12, 2024: actual 9.99M USD, estimate 10.35M USD, surprise -3.45%, Miss. Q2 2025, reported Apr 2, 2025: actual -21.64M USD, estimate 3.55M USD, surprise -709.22%, Miss. Q3 2025, reported Sep 30, 2025: actual 31.36M USD, estimate 23.9M USD, surprise +31.22%, Beat. Q1 2026, reported Mar 31, 2026: actual 3.53M USD, estimate 51.55M USD, surprise -93.15%, Miss. Q3 2026, reported Sep 29, 2026: actual —, estimate 23.56M USD, surprise —, Comparison unavailable.

NBTX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding NBTX

Funds reporting this stock among their holdings, ordered by reported position size.

ActivePassive International Equity ETF logoActivePassive International Equity ETFAPIE
Market value
71.73K
Weight
0.01%
AUM
953.79M USD
Expense ratio
0.45%
Price / 1D
$39.766+1.16%

Continue in GoAI

Research NBTX

research.disclaimer